Completed PHASE1 INTERVENTIONAL 2-arm NCT01751269

Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects.

Sponsor: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

Conditions Bacterial Infections Healthy Volunteers

Interventions Placebo RPX7009

Updated 6 times since 2017 Last updated: Jul 22, 2013 Started: Dec 31, 2012 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Bacterial Infections and Healthy Volunteers, this trial is completed. The trial is conducted by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) and has accumulated 6 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

Data source: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Adelaide, Australia